Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

Rida selected "Best Of ASCO"

Each year, an ASCO committee selects the abstracts that represent the "foremost research in oncology today." These abstracts are then highlighted for presentation and discussion at the Best of ASCO Meetings.

Check out the 1:45 PM – 2:30 PM time slot:
http://boa2011.asco.org/BestofASCOSEATTLE/MeetingProgram/ProgramAgenda.aspx

Sarcoma
William Tap, MD - University of Calfornia, Los Angeles
Abstract #10005: Results of the phase 3, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). (Sant P. Chawla, MD)